LVAD Developers Look To Medicare Coverage Decision To Offset Trial Costs
This article was originally published in The Gray Sheet
Executive Summary
Launch of clinical trials for the DeBakey LVAD as destination therapy for end-stage heart failure patients is contingent on CMS issuing a national coverage decision for the expanded claim, MicroMed maintains